Head-to-head evidence
MB12 vs Penpulimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
MB12
Developed by Laboratorio Elea Phoenix S.A.
NCT05668650 · Phase 3 · status unknown
This is a randomized, double-blind, active-controlled trial with over 170 patients, but its primary comparison is a pharmacokinetic equivalence check between MB12 and the reference drug rather than a clinical efficacy comparison. No results have been posted yet.
Penpulimab
Marketed by Akeso
NCT03866993 · Phase 3 · completed
This randomized, placebo-controlled trial kept participants, care providers, investigators and outcome assessors blind to treatment assignment, with disease progression assessed by an independent radiology committee. Its primary endpoint, progression-free survival, was clearly met, roughly doubling median progression-free survival versus placebo plus chemotherapy.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: MB12's landscape · Penpulimab's landscape